The potential of transcriptomic profiling to predict immune-checkpoint inhibitor (ICIs) response in locally advanced (La) and metastatic urothelial carcinoma (mUC).

被引：0
|
作者：
Caramelo, Belen
Munoz Unceta, Nerea
Freire, Javier
Varela, Ignacio
Martin, David
Del Carmen, Sofia
Azueta, Ainara
Diaz, Pilar
Garcia-Berbel, Pilar
Sagastibelza Marinelarena, Naiara
Rey-Cardenas, Macarena
Castellano, Daniel
Climent, Miguel Angel
Puente, Javier
Irure, Juan
Revuelta, Laura
Genre, Fernanda
Cacho, Diego
Gomez, Javier
Duran, Ignacio
机构：
[1] IDIVAL, Inst Invest Valdecilla, Santander, Cantabria, Spain
[2] Hosp Univ Marques de Valdecilla, Santander, Cantabria, Spain
[3] IBBTEC, Inst Biomed & Biotecnol Cantabria, Santander, Cantabria, Spain
[4] Hosp Donostia, San Sebastian, Spain
[5] Hosp Univ 12 Octubre, Madrid, Spain
[6] Hosp Univ 12 Octubre, Serv Oncol Med, Madrid, Spain
[7] Inst Valenciano Oncol, Valencia, Spain
[8] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain
[9] Hosp Univ Marques de Valdecilla, Dept Med Oncol, Santander, Cantabria, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-11076; 261-566-9718-9794; 298-4768-3691-2722-5055; 283-2494; 283-183-138-12268; 298-4768-12362; 261-492-5651-9270-5657; 6; 5; 3; 2; 38092-27449; 38092-25821; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：668 / 668
页数：1
相关论文
共 50 条
  • [1] Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).
    Agarwal, Archana
    Nassar, Amin
    Pond, Gregory Russell
    Barletta, Justine A.
    Acosta, Andres
    Abou Alaiwi, Sarah
    Curran, Catherine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).
    Vitale, Nuzzo Pier
    Pond, Gregory Russell
    Abou Alaiwi, Sarah
    Nassar, Amin
    Flippot, Ronan
    Choueiri, Toni K.
    Harshman, Lauren Christine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).
    Labriola, Matthew
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    White, James R.
    Weingartner, Elizabeth
    Kong, Eric
    Simone, Peter
    Papp, Eniko
    Gerding, Kelly
    Simmons, John
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
    Reyes, Kevin R.
    Zhang, Li
    Zhu, Xiaolin
    Jindal, Tanya
    Deshmukh, Prianka
    de Kouchkovsky, Ivan
    Kumar, Vipul
    Maldonado, Edward
    Kwon, Daniel H.
    Chan, Emily
    Porten, Sima P.
    Borno, Hala
    Bose, Rohit
    Desai, Arpita
    Aggarwal, Rahul Raj
    Small, Eric Jay
    Fong, Lawrence
    Chou, Jonathan
    Friedlander, Terence W.
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma
    Hanna, Kirollos S.
    PHARMACOTHERAPY, 2017, 37 (11): : 1391 - 1405
  • [6] CIMUC: Chemotherapy following Immune checkpoints inhibitors in patients with locally advanced or metastatic urothelial carcinoma (la/mUC).
    Meynard, Lucie
    Dinart, Derek
    Flechon, Aude
    Saldana, Carolina
    Lefort, Felix
    Gravis, Gwenaelle
    Thiery-Vuillemin, Antoine
    Cancel, Mathilde
    Coquan, Elodie
    Ladoire, Sylvain
    Maillet, Denis
    Rolland, Frederic
    Boughalem, Elouen
    Martin, Sophie
    Laramas, Mathieu
    Crouzet, Laurence
    Abbar, Baptiste
    Falkowski, Sabrina
    Pouessel, Damien
    Roubaud, Guilhem
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [7] GENOMIC BIOMARKERS FOR IMMUNE-CHECKPOINT BLOCKADE RESPONSE IN METASTATIC UPPER TRACT UROTHELIAL CARCINOMA
    Silagy, Andrew W.
    DiNatale, Renzo G.
    Chowell, Diego
    Makarov, Vlad
    Pietzak, Eugene
    Solit, David
    Berger, Michael
    Hakimi, A. Ari
    Reznik, Eduard
    Bajorin, Dean
    Chan, Timothy A.
    Coleman, Jonathan A.
    JOURNAL OF UROLOGY, 2020, 203 : E379 - E379
  • [8] Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study
    Kim, E.
    Kim, J. H.
    Chu, J.
    Lee, Y-G.
    Im, H-S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1214 - S1214
  • [9] The effect of antibiotic use on immune-checkpoint inhibitor efficacy in patients with advanced urothelial carcinoma.
    Khan, Mohammad
    Radakovich, Nathan
    Rini, Brian, I
    Mian, Omar Y.
    Ornstein, Moshe Chaim
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
    Meynard, Lucie
    Dinart, Derek
    Delaunay, Blandine
    Flechon, Aude
    Saldana, Carolina
    Lefort, Felix
    Gravis, Gwenaelle
    Thiery-Vuillemin, Antoine
    Cancel, Mathilde
    Coquan, Elodie
    Ladoire, Sylvain
    Maillet, Denis
    Rolland, Frederic
    Boughalem, Elouen
    Martin, Sophie
    Laramas, Mathieu
    Crouzet, Laurence
    Abbar, Baptiste
    Falkowski, Sabrina
    Pouessel, Damien
    Roubaud, Guilhem
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : 43 - 53
12345